Insulet
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Trade Insulet 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About PODD
Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals.
CEOAshley A. McEvoy
CEOAshley A. McEvoy
Employees3,900
Employees3,900
HeadquartersActon, Massachusetts
HeadquartersActon, Massachusetts
Founded2000
Founded2000
Employees3,900
Employees3,900
PODD Key Statistics
Market cap22.97B
Market cap22.97B
Price-Earnings ratio94.82
Price-Earnings ratio94.82
Dividend yield—
Dividend yield—
Average volume902.20K
Average volume902.20K
High today—
High today—
Low today—
Low today—
Open price$327.54
Open price$327.54
Volume0.00
Volume0.00
52 Week high$354.88
52 Week high$354.88
52 Week low$230.05
52 Week low$230.05
Stock Snapshot
As of today, Insulet(PODD) shares are valued at $326.80. The company's market cap stands at 22.97B, with a P/E ratio of 94.82.
On 2025-11-28, Insulet(PODD) shares started trading at $327.54, with intraday highs of — and lows of —.
Trading activity shows a volume of 0, compared to an average daily volume of 902.2K.
Over the past 52 weeks, Insulet(PODD) stock has traded between a high of $354.88 and a low of $230.05.
Over the past 52 weeks, Insulet(PODD) stock has traded between a high of $354.88 and a low of $230.05.
PODD News
Simply Wall St 2d
How Insulet’s New Omnipod Roadmap and Growth Targets Are Shaping Its Investment StoryAt its recent Investor Day held prior to today, Insulet Corporation announced a long-term growth plan featuring new Omnipod product launches and ambitious reven...
Analyst ratings
86%
of 29 ratingsBuy
86.2%
Hold
13.8%
Sell
0%
People also own
Based on the portfolios of people who own PODD. This list is generated using Robinhood data, and it’s not a recommendation.